HomeAI · summaries
Storia in 4 fonti
Bausch + Lomb flops in ph. 2 with Xiidra and Miebo but advances combo to ph. 3
Bausch + Lomb has come up short in a phase 2 trial, testing its combination of dry eye disease drugs Xiidra and Miebo. | Bausch + Lomb has come up short in a phase 2 trial, testing its combination of dry-eye disease drugs Xiidra and Miebo. While the study missed its primary endpoint, the Ontario eye care specialist has seen enough promise in the combo to advance it to phase 3 development, it said on Tuesday.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Exclusive: Bausch + Lomb plans Ph3 trial for dry eye drop, despite missing mid-stage goal
Bausch+Lomb's Xiidra/Miebo combo drop missed Phase 2 primary endpoint but CEO Brent Saunders calls it positive; Phase 3 planned with FDA's 15-day readout approval.
- ·
morningstar.com
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
